Report: Big Pharma Needs More Open Innovation
Deanna Pogorelc (Philadelphia, PA) — Over the next few years, we’ll likely be seeing more stories along the lines of Merck’s $90 million translational research center for scientists, entrepreneurs and venture capitalists; Sanofi’s partnership with Third Rock Ventures to launch a new biotech company; and Johnson & Johnson, GSK and Index Ventures’ new investment fund.Read… Read more »